Addition of Ganitumab Not Effective for Metastatic Pancreatic Cancer

Share this content:
Addition of ganitumab to gemcitabine did not improve overall survival in unselected patients with metastatic pancreatic cancer.
Addition of ganitumab to gemcitabine did not improve overall survival in unselected patients with metastatic pancreatic cancer.

According to a study published in the journal Annals of Oncology, researchers have found that the addition of ganitumab to gemcitabine did not improve overall survival in unselected patients with metastatic pancreatic cancer.

For the double-blind, phase 3 study, researchers sought to assess the efficacy and safety of ganitumab plus gemcitabine versus gemctiabine alone as first-line treatment of metastatic pancreatic cancer.

Researchers enrolled 800 patients and randomly assigned them 2:2:1 to receive intravenous gemcitabine 1000mg/m2 on days 1, 8, and 15 of each 28-day cycle plus placebo, ganitumab 12mg/kg, or ganitumab 20mg/kg on days 1 and 15 of each cycle.

RELATED: High Resection Rates in Pancreatic Cancer with mFOLFIRINOX, Aggressive Surgery

Results showed that the median overall survival was 7.2 months (95% CI: 6.3 - 8.2) in the placebo arm, 7.0 months (95% CI: 6.2 - 8.5) in the ganitumab 12mg/kg arm (HR = 1.00; 95% CI: 0.82 - 1.21; P = 0.494), and 7.1 months (95% CI: 6.4 - 8.5) in the ganitumab 20mg/kg arm (HR = 0.97; 95% CI: 0.76 - 1.23; = 0.520).

In addition, progression-free survival was 3.7 months in the placebo arm, 3.6 months in the ganitumab 12mg/kg arm (HR = 1.00; 95% CI: 0.84 - 1.20; P = 0.520), and 3.7 months in the ganitumab 20mg/kg arm (HR = 0.97; 95% CI: 0.77 - 1.22; = 0.403).

In regard to safety, no unexpected toxicity was observed with ganitumab in combination with gemcitabine.

Reference

  1. Fuchs CS, Azevedo S, Okusaka T, et al. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial. Ann Oncol. 2015. [Epub ahead of print]. doi: 10.1093/annonc/mdv027.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters